Indexed by:
Journal Papers
First Author:
Zhang, Xiujuan
Correspondence Author:
Zhang, XJ; He, GH (corresponding author), Dalian Univ Technol, Sch Petr & Chem Engn, State Key Lab Fine Chem, Panjin 124221, Peoples R China.; He, GH (corresponding author), Dalian Univ Technol, Sch Chem Engn, R&D Ctr Membrane Sci & Technol, Dalian 116024, Peoples R China.
Co-author:
Li, Wenjuan,Dou, Xiang,Nan, De,He, Gaohong
Date of Publication:
2020-06-01
Journal:
APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
Included Journals:
PubMed、SCIE
Document Type:
J
Volume:
191
Issue:
2
Page Number:
511-527
ISSN No.:
0273-2289
Key Words:
Astaxanthin; Calcium alginate microspheres; HepG2 cells; THLE-2 cells;
Glyco-metabolism
Abstract:
Astaxanthin (AST) has attracted great interests in the scientific world because of its anti-oxidative, anti-inflammatory properties. And biodegradable materials, like chitosan, have been employed as the AST carrier to protect it from degradation and promote its bioavailability. However, the lack of pH responsiveness of these materials usually could not protect AST from the strong acidic gastric juices. In this study, calcium alginate (CA) microspheres, a pH responsive and biodegradable material, were prepared by a modified double emulsion technology and used as the AST encapsulation agent. Experimental results showed that the microparticles formed had a good degree of roundness, dispersity, encapsulation efficiency, and pH responsiveness. Cellular studies demonstrated that AST encapsulated in CA could inhibit hepatoma cells (HepG2 cell line) but it has relatively small or no impact on control hepatocytes (THLE-2 cell line). Furthermore, investigation of the underlying mechanism indicated that recovery of disorder of glucose metabolism by inhibiting aerobic glycolysis and promoting tricarboxylic acid cycle played an important part in the cell proliferation inhibition of hepatoma cells. As suggested above, AST could be a very promising therapeutic agent of liver cancer in clinical trials.
Translation or Not:
no
